Evaluation of Efficacy and Safety of Intella Dermal Filler in Moderate to Severe Nasolabial Folds

Inclusion criteria

• Participants must have moderate to severe nasolabial folds based on the Allergan scale.
• Participants must be able to comply with the visit schedule and study procedures.
• Participants must have signed the informed consent form and agreed to the 6-month follow-up

Exclusion criteria

• History of type 1 hypersensitivity reactions or anaphylaxis.
• Previous allergy or sensitivity to filler components or lidocaine.
• History of hypertrophic or keloid scar formation or bleeding disorders in the nasolabial area.
• Presence of active inflammatory processes, infection, or lesions (malignant/non-malignant) in the nasolabial area.
• History of autoimmune diseases/immunodeficiency or use of immunosuppressive drugs within 6 months prior to or during the study.
• Use of antiplatelet drugs within 72 hours prior to treatment and anticoagulants within 2 weeks prior to or during treatment.
• Pregnancy, breastfeeding, or planning pregnancy in the near future during the study.
• Use of cosmetic treatments in recent months or plans to undergo such treatments in the near future during the study, including:

• Botulinum toxin type A injections below the zygomatic arch within 6 months prior to study entry.
• Non-permanent dermal filler injections (e.g., bovine collagen, hyaluronic acid) in facial areas within 1 year prior to study entry.
• Use of calcium hydroxyapatite, poly-L-lactic acid, or permanent fillers (e.g., silicone) in facial areas at any time before or during the study.
• Deep skin peeling procedures such as chemical peeling, laser, dermabrasion, radio frequency within 6 months prior to study entry.
• Superficial skin peeling within 6 weeks prior to study entry.
• Other reasons that, according to the investigator's judgment, make the patient unsuitable for study participation (e.g., uncertainty about patient cooperation).